Topic summary

What a regulator's shortage notice actually authorises — what changed since

Sourcing › Regulatory research use only EMA FDA compounding MHRA Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 27, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

j.marchettiTL227 Jul 2025#1

The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it.

Asking what a regulator's document actually says, since the summaries of it disagree.

I have the primary document open and two secondhand accounts of it that cannot both be right. The primary document is narrower than either.

My question is whether I am reading the scope of it correctly, and what the correct reading rules out as well as what it permits.

57 likes 12mo

r.vukovicTL2 Solution24 Aug 2025#4

Narrowing post #3, because the general version has more than one answer.

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

That is the version I would defend. It is not the version I started with.

8 likes 11mo

z.okonkwoTL22 Oct 2025#10

Adding thanks rather than a view. I do not have a view worth the space.

30 likes 10mo

i.amankwahTL214 Nov 2025#18

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

This is where my knowledge stops and I would rather mark the edge than blur it.

28 likes 8mo

j.sandvikTL222 Dec 2025#26

Adding the measurement that post #24 says would settle it.

Shortage notifications are published by several regulators and are the authoritative source for a question this community usually answers from anecdote.

The literature is thinner on this than the confidence in the thread implies.

25 likes 7mo

Read the full topic (27 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: How compounding permissions changed when supply normalised Sourcing › Regulatory MHRA personal import research use only How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about compounding permissions in a thread last…	+72	77	1.5k	1d
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of it disagree. I have…		2	62k	15mo
Research-use-only labelling: what it means and what it does not Sourcing › Regulatory compounding research use only EMA FDA Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. A labelling question, and I would like the answer to be…	+100	110	37k	5mo
How compounding permissions changed when supply normalised Sourcing › Regulatory personal import EMA compounding research use only Solved Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised I was wrong about compounding permissions in a thread last spring and I would like to…	+30	34	51k	16mo
Pharmaceutical compounding rules, summarised from primary sources Sourcing › Regulatory MHRA EMA research use only Closed Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of…	+135	163	46k	17mo

Related topics — sharing the tags research use only, EMA, FDA

Topic	Participants	Replies	Views	Activity
Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds needs a source mislabelling research use only custom synthesis Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Melanocortin agonists, and specifically the version of it that the…	+7	11	5.5k	20mo
Currency conversion and the cost you did not see Sourcing › Payments payments research use only documentation quality Currency conversion and the cost you did not see — setting out what I have, and where I think it stops being reliable. Currency and fees, set out so that the comparison can be checked. Quoted amount,…		2	44k	2mo
Sequence verification for an obscure compound: how it is done Compounds › Other compounds needs a source custom synthesis research use only mislabelling Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Asking about sequence verification directly, because I have…	+104	114	10k	12mo
Prescription requirements and telehealth models Sourcing › Regulatory FDA compounding research use only MHRA Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. Proposing that prescription requirements and telehealth models deserves a…	+91	97	5.4k	7mo
Coverage in the US: a map of the usual obstacles Regional › North America FDA insurance telehealth compounding Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on coverage. The general claim is fine; I…	+46	50	7.9k	5mo